{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T21:21:36Z","timestamp":1792790496055,"version":"4.5.0"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,8,7]]},"DOI":"10.7759\/cureus.27763","type":"journal-article","created":{"date-parts":[[2022,8,8]],"date-time":"2022-08-08T06:37:38Z","timestamp":1659940658000},"source":"Crossref","is-referenced-by-count":5,"title":["Exploring a New Entity of Single-Agent Pembrolizumab-Associated Hypophysitis"],"prefix":"10.7759","author":[{"given":"Eric","family":"Balti","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Verhaeghe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vibeke","family":"Kruse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stijn","family":"Roels","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Coremans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1007\/s11102-015-0671-4","article-title":"Immunotherapy and hypophysitis: clinical presentation, treatment, and biologic insights","volume":"19","author":"Faje A","year":"2016","unstructured":"Faje A. Immunotherapy and hypophysitis: clinical presentation, treatment, and biologic insights. Pituitary. 2016, 19:82-92. 10.1007\/s11102-015-0671-4","journal-title":"Pituitary"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1530\/EJE-19-0238","article-title":"Hypophysitis secondary to nivolumab and pembrolizumab is a clinical entity distinct from ipilimumab-associated hypophysitis","volume":"181","author":"Faje A","year":"2019","unstructured":"Faje A, Reynolds K, Zubiri L, et al.. Hypophysitis secondary to nivolumab and pembrolizumab is a clinical entity distinct from ipilimumab-associated hypophysitis. Eur J Endocrinol. 2019, 181:211-9. 10.1530\/EJE-19-0238","journal-title":"Eur J Endocrinol"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1053\/j.seminoncol.2018.09.002","article-title":"Cancer immunotherapy-associated hypophysitis","volume":"45","author":"Solinas C","year":"2018","unstructured":"Solinas C, Porcu M, De Silva P, et al.. Cancer immunotherapy-associated hypophysitis. Semin Oncol. 2018, 45:181-6. 10.1053\/j.seminoncol.2018.09.002","journal-title":"Semin Oncol"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgab672","article-title":"Hypophysitis, the growing spectrum of a rare pituitary disease","volume":"107","author":"Langlois F","year":"2022","unstructured":"Langlois F, Varlamov EV, Fleseriu M. Hypophysitis, the growing spectrum of a rare pituitary disease. J Clin Endocrinol Metab. 2022, 107:10-28. 10.1210\/clinem\/dgab672","journal-title":"J Clin Endocrinol Metab"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1016\/j.crad.2020.12.028","article-title":"The imaging of immunotherapy-related hypophysitis and other pituitary lesions in oncology patients","volume":"76","author":"Lasocki A","year":"2021","unstructured":"Lasocki A, Iravani A, Galligan A. The imaging of immunotherapy-related hypophysitis and other pituitary lesions in oncology patients. Clin Radiol. 2021, 76:325-32. 10.1016\/j.crad.2020.12.028","journal-title":"Clin Radiol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1007\/s11060-020-03396-w","article-title":"Current status and treatment modalities in metastases to the pituitary: a systematic review","volume":"146","author":"Ng S","year":"2020","unstructured":"Ng S, Fomekong F, Delabar V, et al.. Current status and treatment modalities in metastases to the pituitary: a systematic review. J Neurooncol. 2020, 146:219-27. 10.1007\/s11060-020-03396-w","journal-title":"J Neurooncol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2019.06.020","article-title":"Machine learning defined diagnostic criteria for differentiating pituitary metastasis from autoimmune hypophysitis in patients undergoing immune checkpoint blockade therapy","volume":"119","author":"Mekki A","year":"2019","unstructured":"Mekki A, Dercle L, Lichtenstein P, et al.. Machine learning defined diagnostic criteria for differentiating pituitary metastasis from autoimmune hypophysitis in patients undergoing immune checkpoint blockade therapy. Eur J Cancer. 2019, 119:44-56. 10.1016\/j.ejca.2019.06.020","journal-title":"Eur J Cancer"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdx225","article-title":"Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"28","author":"Haanen JB","year":"2017","unstructured":"Haanen JB, Carbonnel F, Robert C, Kerr KM, Peters S, Larkin J, Jordan K. Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2017, 28:iv119-42. 10.1093\/annonc\/mdx225","journal-title":"Ann Oncol"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1530\/EDM-19-0102","article-title":"Clinical heterogeneity of hypophysitis secondary to PD-1\/PD-L1 blockade: insights from four cases","volume":"2019","author":"Lupi I","year":"2019","unstructured":"Lupi I, Brancatella A, Cosottini M, et al.. Clinical heterogeneity of hypophysitis secondary to PD-1\/PD-L1 blockade: insights from four cases. Endocrinol Diabetes Metab Case Rep. 2019, 2019:10.1530\/EDM-19-0102","journal-title":"Endocrinol Diabetes Metab Case Rep"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1007\/s12020-014-0199-9","article-title":"Ipilimumab, not just another anti-cancer therapy: hypophysitis as side effect illustrated by four case-reports","volume":"47","author":"Marlier J","year":"2014","unstructured":"Marlier J, Cocquyt V, Brochez L, Van Belle S, Kruse V. Ipilimumab, not just another anti-cancer therapy: hypophysitis as side effect illustrated by four case-reports. Endocrine. 2014, 47:878-83. 10.1007\/s12020-014-0199-9","journal-title":"Endocrine"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2017.10.023","article-title":"Late-onset adrenal insufficiency more than 1 year after stopping pembrolizumab","volume":"13","author":"Boudjemaa A","year":"2018","unstructured":"Boudjemaa A, Rousseau-Bussac G, Monnet I. Late-onset adrenal insufficiency more than 1 year after stopping pembrolizumab. J Thorac Oncol. 2018, 13:e39-40. 10.1016\/j.jtho.2017.10.023","journal-title":"J Thorac Oncol"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.2169\/internalmedicine.3008-19","article-title":"Progression of hypopituitarism and hypothyroidism after treatment with pembrolizumab in a patient with adrenal metastasis from non-small-cell lung cancer","volume":"58","author":"Yamagata S","year":"2019","unstructured":"Yamagata S, Kageyama K, Takayasu S, Asari Y, Makita K, Terui K, Daimon M. Progression of hypopituitarism and hypothyroidism after treatment with pembrolizumab in a patient with adrenal metastasis from non-small-cell lung cancer. Intern Med. 2019, 58:3557-62. 10.2169\/internalmedicine.3008-19","journal-title":"Intern Med"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1007\/s11102-021-01141-8","article-title":"Isolated ACTH deficiency induced by cancer immunotherapy: a systematic review","volume":"24","author":"Iglesias P","year":"2021","unstructured":"Iglesias P, S\u00e1nchez JC, D\u00edez JJ. Isolated ACTH deficiency induced by cancer immunotherapy: a systematic review. Pituitary. 2021, 24:630-43. 10.1007\/s11102-021-01141-8","journal-title":"Pituitary"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.3390\/jcm9103280","article-title":"Anti-PD1 and anti-PDL1-induced hypophysitis: a cohort study of 17 patients with longitudinal follow-up","volume":"9","author":"Levy M","year":"2020","unstructured":"Levy M, Abeillon J, Dalle S, et al.. Anti-PD1 and anti-PDL1-induced hypophysitis: a cohort study of 17 patients with longitudinal follow-up. J Clin Med. 2020, 9:3280. 10.3390\/jcm9103280","journal-title":"J Clin Med"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.15465","article-title":"Pembrolizumab-induced hypophysitis with isolated adrenocorticotropic hormone (ACTH) deficiency: a rare immune-mediated adverse event","volume":"13","author":"Doodnauth AV","year":"2021","unstructured":"Doodnauth AV, Klar M, Mulatu YS, Malik ZR, Patel KH, McFarlane SI. Pembrolizumab-induced hypophysitis with isolated adrenocorticotropic hormone (ACTH) deficiency: a rare immune-mediated adverse event. Cureus. 2021, 13:e15465. 10.7759\/cureus.15465","journal-title":"Cureus"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.12659\/AJCR.931639","article-title":"Isolated adrenocorticotropic hormone deficiency associated with severe hyperkalemia during pembrolizumab therapy in a patient with ureteral cancer and an ileal conduit: a case report and literature review","volume":"22","author":"Hinata Y","year":"2021","unstructured":"Hinata Y, Ohara N, Sakurai Y, et al.. Isolated adrenocorticotropic hormone deficiency associated with severe hyperkalemia during pembrolizumab therapy in a patient with ureteral cancer and an ileal conduit: a case report and literature review. Am J Case Rep. 2021, 22:e931639. 10.12659\/AJCR.931639","journal-title":"Am J Case Rep"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2019.102454","article-title":"Isolated autoimmune adrenocorticotropic hormone deficiency: from a rare disease to the dominant cause of adrenal insufficiency related to check point inhibitors","volume":"19","author":"Percik R","year":"2020","unstructured":"Percik R, Shlomai G, Tirosh A, et al.. Isolated autoimmune adrenocorticotropic hormone deficiency: from a rare disease to the dominant cause of adrenal insufficiency related to check point inhibitors. Autoimmun Rev. 2020, 19:102454. 10.1016\/j.autrev.2019.102454","journal-title":"Autoimmun Rev"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1186\/s40842-019-0092-9","article-title":"Isolated ACTH deficiency during single-agent pembrolizumab for squamous cell lung carcinoma: a case report","volume":"6","author":"Tanaka S","year":"2020","unstructured":"Tanaka S, Kushimoto M, Nishizawa T, et al.. Isolated ACTH deficiency during single-agent pembrolizumab for squamous cell lung carcinoma: a case report. Clin Diabetes Endocrinol. 2020, 6:1. 10.1186\/s40842-019-0092-9","journal-title":"Clin Diabetes Endocrinol"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1093\/ehjcr\/yty038","article-title":"Cardiac tamponade and adrenal insufficiency due to pembrolizumab: a case report","volume":"2","author":"Oristrell G","year":"2018","unstructured":"Oristrell G, Ba\u00f1eras J, Ros J, Mu\u00f1oz E. Cardiac tamponade and adrenal insufficiency due to pembrolizumab: a case report. Eur Heart J Case Rep. 2018, 2:yty038. 10.1093\/ehjcr\/yty038","journal-title":"Eur Heart J Case Rep"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.4158\/ACCR-2019-0585","article-title":"A common pituitary autoantibody in two patients with immune checkpoint inhibitor-mediated hypophysitis: ZCCHC8","volume":"6","author":"Leiter A","year":"2020","unstructured":"Leiter A, Gnjatic S, Fowkes M, Kim-Schulze S, Laface I, Galsky MD, Gallagher EJ. A common pituitary autoantibody in two patients with immune checkpoint inhibitor-mediated hypophysitis: ZCCHC8. AACE Clin Case Rep. 2020, 6:e151-60. 10.4158\/ACCR-2019-0585","journal-title":"AACE Clin Case Rep"},{"key":"ref21","article-title":"Pembrolizumab Induced Hypophysitis in a Patient Allergic to Triamcinolone: An Increasingly Recognized Endocrinopathy Related to Immunotherapy","volume":"29","author":"Chowdhury RH","year":"2020","unstructured":"Chowdhury RH, Hasan MN. Pembrolizumab Induced Hypophysitis in a Patient Allergic to Triamcinolone: An Increasingly Recognized Endocrinopathy Related to Immunotherapy. Mymensingh Med J. 2020, 29:1021-5.","journal-title":"Mymensingh Med J"},{"key":"ref22","article-title":"Hypophysitis and other autoimmune complications related to immune checkpoints inhibitors\u00b4 treatment: Spectrum of imaging appearances","volume":"39","author":"Malikova H","year":"2018","unstructured":"Malikova H, Holesta M, Fialova A, Arenbergerova M, Weichet J. Hypophysitis and other autoimmune complications related to immune checkpoints inhibitors\u00b4 treatment: Spectrum of imaging appearances. Neuro Endocrinol Lett. 2018, 39:196-204.","journal-title":"Neuro Endocrinol Lett"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.19726","article-title":"Immunotherapy: a case series","volume":"13","author":"Do TV","year":"2021","unstructured":"Do TV, Gudipati MK, Ganti SS, Depa J, Sajnani K. Immunotherapy: a case series. Cureus. 2021, 13:e19726. 10.7759\/cureus.19726","journal-title":"Cureus"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1002\/ccr3.4305","article-title":"Isolated adrenocorticotropin deficiency induced by pembrolizumab for hypopharyngeal cancer: a case report","volume":"9","author":"Yamamoto K","year":"2021","unstructured":"Yamamoto K, Tokumasu K, Oka K, Hasegawa K, Otsuka F. Isolated adrenocorticotropin deficiency induced by pembrolizumab for hypopharyngeal cancer: a case report. Clin Case Rep. 2021, 9:e04305. 10.1002\/ccr3.4305","journal-title":"Clin Case Rep"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.2217\/imt-2021-0061","article-title":"Clinical course and management of pembrolizumab-associated isolated adrenocorticotrophic hormone deficiency: a new case and literature review","volume":"13","author":"O\u011fuz SH","year":"2021","unstructured":"O\u011fuz SH, \u00dcnl\u00fct\u00fcrk U, Aksoy S, Erbas T. Clinical course and management of pembrolizumab-associated isolated adrenocorticotrophic hormone deficiency: a new case and literature review. Immunotherapy. 2021, 13:1157-63. 10.2217\/imt-2021-0061","journal-title":"Immunotherapy"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1159\/000505687","article-title":"A case of isolated adrenocorticotropic hormone deficiency caused by pembrolizumab","volume":"13","author":"Bekki T","year":"2020","unstructured":"Bekki T, Takakura Y, Kochi M, et al.. A case of isolated adrenocorticotropic hormone deficiency caused by pembrolizumab. Case Rep Oncol. 2020, 13:200-6. 10.1159\/000505687","journal-title":"Case Rep Oncol"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1097\/CAD.0000000000001129","article-title":"Hypophysitis secondary to pembrolizumab: a case report and review of the literature","volume":"33","author":"Montero P\u00e9rez O","year":"2022","unstructured":"Montero P\u00e9rez O, S\u00e1nchez Escudero L, Guzm\u00e1n Ramos MI, Avi\u00f1\u00f3 Tarazona V. Hypophysitis secondary to pembrolizumab: a case report and review of the literature. Anticancer Drugs. 2022, 33:94-9. 10.1097\/CAD.0000000000001129","journal-title":"Anticancer Drugs"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.2217\/mmt-2018-0009","article-title":"Hypophysitis induced by immune checkpoint inhibitors in a Scottish melanoma population","volume":"6","author":"Wei KZ","year":"2019","unstructured":"Wei KZ, Baxter M, Casasola R. Hypophysitis induced by immune checkpoint inhibitors in a Scottish melanoma population. Melanoma Manag. 2019, 6:MMT13. 10.2217\/mmt-2018-0009","journal-title":"Melanoma Manag"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-000779","article-title":"Pituitary dysfunction induced by immune checkpoint inhibitors is associated with better overall survival in both malignant melanoma and non-small cell lung carcinoma: a prospective study","volume":"8","author":"Kobayashi T","year":"2020","unstructured":"Kobayashi T, Iwama S, Yasuda Y, et al.. Pituitary dysfunction induced by immune checkpoint inhibitors is associated with better overall survival in both malignant melanoma and non-small cell lung carcinoma: a prospective study. J Immunother Cancer. 2020, 8:e000779. 10.1136\/jitc-2020-000779","journal-title":"J Immunother Cancer"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.3174\/ajnr.A6692","article-title":"MRI findings of immune checkpoint inhibitor-induced hypophysitis: possible association with fibrosis","volume":"41","author":"Kurokawa R","year":"2020","unstructured":"Kurokawa R, Ota Y, Gonoi W, et al.. MRI findings of immune checkpoint inhibitor-induced hypophysitis: possible association with fibrosis. AJNR Am J Neuroradiol. 2020, 41:1683-9. 10.3174\/ajnr.A6692","journal-title":"AJNR Am J Neuroradiol"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-019-0218-0","article-title":"Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance","volume":"16","author":"Martins F","year":"2019","unstructured":"Martins F, Sofiya L, Sykiotis GP, et al.. Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance. Nat Rev Clin Oncol. 2019, 16:563-80. 10.1038\/s41571-019-0218-0","journal-title":"Nat Rev Clin Oncol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/106225-exploring-a-new-entity-of-single-agent-pembrolizumab-associated-hypophysitis","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T19:37:06Z","timestamp":1707507426000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/106225-exploring-a-new-entity-of-single-agent-pembrolizumab-associated-hypophysitis"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,7]]},"references-count":31,"URL":"https:\/\/doi.org\/10.7759\/cureus.27763","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2022,8,7]]}}}